Combining SBRT with PD-1 Blockade for Metastatic Kidney Cancer
Response to the Combination of Stereotactic Body Radiation Therapy and Concurrent PD-1 Blockade in Patients With Metastatic Renal Cell Carcinoma: a Retrospective Study
This study is testing if combining a type of targeted radiation therapy with a new immune treatment can help people with advanced kidney cancer feel better and have fewer side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06327178 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the systemic anti-tumor activity and safety of combining stereotactic body radiotherapy (SBRT) with concurrent PD-1 blockade in patients with metastatic clear renal cell carcinoma. The study focuses on assessing the objective response rate in non-irradiated lesions and monitoring the incidence of adverse events. By exploring the abscopal effects of SBRT, the research seeks to enhance the understanding of immune responses triggered by this treatment combination.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with advanced stage IV renal cell carcinoma who have previously received SBRT and PD-1 blockade treatment.
Not a fit: Patients with additional malignancies that are progressing or require active treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for patients with metastatic kidney cancer by enhancing systemic immune responses.
How similar studies have performed: Previous studies have shown promising results with similar combinations of radiotherapy and immune checkpoint inhibitors, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age≥18 years at the time of signing informed consent; * Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8); * Previously received SBRT and concurrent PD-1 blockade treatment； * Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria. Exclusion Criteria: * Patients who cannot be adequately followed up; * Has a known additional malignancy that is progressing or requires active treatment.
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Guozhu Xie
- Email: xieguozhu@126.com
- Phone: 02062787693
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.